These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26225258)

  • 1. Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making.
    Rowland M; Lesko LJ; Rostami-Hodjegan A
    CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):313-5. PubMed ID: 26225258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation.
    Shepard T; Scott G; Cole S; Nordmark A; Bouzom F
    CPT Pharmacometrics Syst Pharmacol; 2015 Apr; 4(4):221-5. PubMed ID: 26225245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK modeling and simulation in drug research and development.
    Zhuang X; Lu C
    Acta Pharm Sin B; 2016 Sep; 6(5):430-440. PubMed ID: 27909650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency.
    Luzon E; Blake K; Cole S; Nordmark A; Versantvoort C; Berglund EG
    Clin Pharmacol Ther; 2017 Jul; 102(1):98-105. PubMed ID: 27770430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance.
    Jamei M
    Curr Pharmacol Rep; 2016; 2(3):161-169. PubMed ID: 27226953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report.
    Wu F; Mousa Y; Raines K; Bode C; Tsang YC; Cristofoletti R; Zhang H; Heimbach T; Fang L; Kesisoglou F; Mitra A; Polli J; Kim MJ; Fan J; Zolnik BS; Sun D; Zhang Y; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):585-597. PubMed ID: 36530026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PBPK model reporting template for chemical risk assessment applications.
    Tan YM; Chan M; Chukwudebe A; Domoradzki J; Fisher J; Hack CE; Hinderliter P; Hirasawa K; Leonard J; Lumen A; Paini A; Qian H; Ruiz P; Wambaugh J; Zhang F; Embry M
    Regul Toxicol Pharmacol; 2020 Aug; 115():104691. PubMed ID: 32502513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
    Yang Y; Zhang X
    Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives.
    Suarez-Sharp S; Lindahl A; Heimbach T; Rostami-Hodjegan A; Bolger MB; Ray Chaudhuri S; Hens B
    Pharm Res; 2020 May; 37(6):95. PubMed ID: 32405699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
    Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
    Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.